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ABSTRACT
Diabetes is the disease caused by the presence of a high concentration of glucose in the
blood due to a malfunction of the hormone insulin. After the discovery of insulin more
than eighty years ago, different kinds of commercial insulin preparations have been
developed, however none of them is able to replicate the action of normal insulin, and
many have developed side effects in the patients. Insulin analogues that can mimic insulin
functions more effectively are under investigation. The chemical synthesis of these
analogues is necessary in order to study their function; however the current techniques
used give low yields and purity.
In the present work, we propose a new process to produce the interchain disulfide bonds
after the chemical synthesis of the A and B chain of insulin. This procedure is expected to
occur in higher yields than the reported ones.
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1. INTRODUCTION
Insulin is a hormone produced in the b-cells of the pancreas. It regulates the uptake of
glucose into the cells from the blood to use as fuel, the formation of glycogen for storage
in cells, and many anabolic processes like cell growth and cellular protein synthesisi.
Insulin is produced as a response of a high concentration of glucose that occurs after
eating a meal. However, when the level of glucose comes down to the usual physiological
value, insulin release from b-cells slows or stops so glucose returns to the normal 'fasting'
level.
High levels of glucose in the blood are produced by a malfunction of insulin. This
hyperglycemia is the medical disorder known as Diabetes Mellitus. There are two types of
Diabetes: Type 1 is caused by a decrease or a complete cease in the production of insulin
due to the destruction of b-cells, and Type 2 occurs when the body produces an
insufficient amount of insulin or the insulin produced does not function properlyii.
Structure of Insulin
Human insulin monomer, which is the biologically active form of insulin, consists of two
side chains called A-chain and B-chain. The A-chain has 21 aminoacids whereas the B-
chain has 30 aminoacids. These two chains are linked together by disulfide bonds formed
between A7-B7 and A20-B19. In addition, the A-chain contains an intra-chain disulfide
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bridge between A7 and A11iii (Figure 1). These disulfide bonds play an important role in
the construction of its three dimensional structure.
Figure 1. Human Insulin
Insulin can dimerize in the presence of micromolar concentrations of zinc ions, and these
dimmers can associate into hexamers.
Treatment of Diabetes
Because the structure of insulin is highly conserved among species, the first sources of
insulin were the ones produced by cows or pigs (bovine and porcine insulin differs from
human insulin in two and one aminoacid, respectively). However, allergic reactions were
developed in patients due to the impurity of the mixture or to the source itself. The
employ of genetic engineering techniques that uses microorganisms to biosynthesize
proteins, has lead to the production of human insulin (HumulinÒ, Eli Lilly and Company)
which does not cause impurity reaction problems. Actually, there are a few patients that
still use insulin from animals.
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Insulin replacement consists of prandial insulin, basal insulin, and a correction-dose insulin
supplementiv. Prandial insulin is given to mimic the high levels of insulin produced after the
intake of food, basal insulin mimics the small and constant concentration of insulin present
within the cells, and correction-dose regulates pre-meal or between-meal hyperglycemiav.
HumulinÒ R (regular insulin) had nothing added to change the speed or length of its
action. It takes effect rapidly and has a short duration of activity (4 to 12 hours)vi. Because
of this, it was necessary to develop long-acting preparations to reduce the number of
injections necessary to fulfill the insulin requirements. Neutral protamin Hagedorn (NPH,
HumulinÒ N) and insulin zinc (Lente, HumulinÒ L) were introduced. These are
intermediate-acting insulins with a longer duration of activity (up to 24 hours) than that of
regular insulin. These are prandial and basal insulins.
Although these types of insulins improved the life of the patients, most of them have
developed hypoglycemia (low levels of glucose in blood) as a consequence of high levels
of insulin during the fasting state, and continue to exhibit hyperglycemia, mainly in the
postprandial state. As a consequence, new kinds of insulins have been studied. These are
called insulin analogues.
Insulin analogues
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Insulin analogues are insulins whose structure has been modified in order to improve their
absorption, distribution, metabolism and excretion.
The low absorptivity of regular insulin is attributed to the fact that it exists in its hexameric
form in the bottles supplied from pharmacy. Rapid-acting insulin analogues, which are
insulins unable to form hexamers in solution, produce a peak in the activity in the first
hour of injection so they increase the insulin concentration in the postprandial statevii.
Insulin Lispro (HumalogÒ, Eli Lilly and Company) and insulin Aspart (NovoLogÒ, Novo
Nordisk) are two rapid-acting insulin analogues.
Long-acting analogues, like insulin Glargine (LantusÒ, Aventis) and insulin Detemir
(Levemir®, Novo Nordisk), that possess a isoelectric point different than native insulin, are
absorbed and released within hours in the body, so they can act as a replacement of basal
insulin needs in the fasting state.
Although great improvements have been made, the production of new analogues that can
replicate normal insulin secretion is still under investigation.
Production of insulin
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Chemical synthesis of insulin was achieved in the mid-1960s but its high cost makes the
production of insulin in a large scale commercially impossible. However, in order to obtain
new insulin analogues in the laboratory using a strain of E. coli, it is first necessary to
study their mode of action. The chemical synthesis of insulin analogues is an important
preliminary technique used in the production of these analogues in a small scale.
The most challenged task in the synthesis of insulin is the correct formation of the disulfide
bonds after the production of the A and B chains. A few techniques have been
developedviii,ix,x for the formation of these disulfide bond interchains. In the case of insulin,
high yields have not been obtained using these techniques.
The present work proposes a new method for the formation of the disulfide bonds
between the chains, following the solid phase synthesis of each chain (Scheme 1).
1. Solid phase peptide synthesis
Boc-HN-HC-OC-O-H2C
H2C
H2C
CO
HN
PH3C
MBHA-Boc-Asp(a-Bzl)
t-Boc resin
1. Solid phase peptide synthesis
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Scheme 1. Production of insulin
The process illustrated in Scheme 1 consists of five (or four) steps. Step 1 and 2 involve
the solid phase synthesis of each chain using the traditional t-Boc methodology on a
peptide synthesizer. Step 3 is used to obtain the sulfite group attached to the sulfur in a
cysteine side chain when required. Step 4 is the formation of one disulfide interchain bond
between A20 and B19. This bond is constructed by reaction of the S-sulfitecysteine at
position B19 (peptide c) or A20 (peptide b) with the thiol group of the cysteine side chain
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at position A20 (peptide a) or B19 (peptide d), respectively.  Finally, the formation of the
intrachain disulfide bond between A6 and A11 and the second interchain disulfide bond
between A7 and B7 (step 4) are expected to occur by reaction with iodine, I2, which has
been proven to cleave Acm protecting groups9. Acm groups were chosen because they are
stable against strong acids such as HF9, which is used to cleave the peptide from the resin
during step 2.
It is necessary to mention, that the A-chain analogues produced contain Aspartate instead
of Serine at position 12. This modification has been introduced by Zack Kaur at the
DiMarchi laboratory in order to improve the solubility of the chain. The proposed process
(Scheme 1) will be studied using this modification. When the appropriate set of conditions
will be determined to produce insulin, the same conditions will be followed to produce
human insulin, and different analogues.
This report show the preliminary steps in the evaluation of the best sets of conditions
required to obtain the disulfide bonds in the formation of insulin analogues.
2. MATERIALS AND METHODS
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2.1.  General
Standard solid phase peptide synthesis
All amino acids were protected with t-Boc and purchased from Midwest Biotech. The
cysteine thiol groups at positions A6, A7, A11 and B7 were protected with acid stable
Acm groups. The synthesis was carried out on an Applied Biosystem 430A Peptide
Synthesizer.
HPLC analysis
Analytical HPLC was carried out using a on a 46 x 5 cm Zorbax C8 column, which was
eluted using a linear gradient of 90 % CH3CN (gradient A: 10%-80%, 10 min), in 0.1%
aqueous TFA at a flow rate of 1mL/min. The eluate was monitored by measuring the UV
absorption at 214 nm. The system used was a Beckman System Gold.
FPLC analysis
Ion exchange chromatography was carried out on a MonoQ Semi Prep column, eluted
with a linear gradient of 500 mM NaCl (gradient B: 0%-100%, 60 min) in 50 mM
TRIS/7M urea pH 8 at a flow rate of 2 min/mL, while monitoring the UV at 280 nm.
Reverse phase chromatography was carried out on a Pep RP Semi Prep 8494003 column,
eluted with a linear gradient of 50 % CH3CN (gradient C: 0%-100%, 65 min, gradient D:
0%-100%, 120 min) in 0.05 M NH4HCO3 at a flow rate of 2 mL/min, while monitoring
the UV at 280 nm (gradient C) and at 214 nm (gradient D).
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Reverse phase chromatography was also carried out on a Pep RPC 10/16 column, eluted
with a linear gradient of 50 % CH3CN (gradient E: 10%-90%, 120 min, gradient F: 30%-
100, 120 min), in 0.1 % TFA at a flow rate of 2 mL/min, while monitoring the UV at 214
nm.
The FPLC system used was a Pharmacia Biotech attached to a fraction collector Frac-100.
Mass spectrometry
Mass spectral data was obtained using electrospray ionization (ESI) on a PE-Sciex API III
Triple Quadrupole.
Mass spectral data was obtained using a matrix-assisted laser desorption/ionization time-
of-flight (MALDI-TOF) on a Bruker Biflex III spectrometer.
Sulfitolysis
Sulfitolysis of the peptides were obtained by preparing a 10mg/mL solution of the
particular peptide in 50mM TRIS/7 M urea pH 8, 100mM Na2SO3 and 10mM
Na2S4O6.2H2O. The reaction was left for one and a half hour at room temperature.
2.2. Synthesis of A-Chain Insulin Analogues
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0.285 g (0.2 mmol) of MBHA-Boc-Asp(a-Bzl) resin was placed in a standard 60 mL
reaction vessel. The A-Chain D12C(Acm)6,7,11 (a, molecular weight: 2624.99 g/mol)
sequence was entered and run on a modified ABI430A peptide synthesizer using fast Boc-
DEPBT single coupling. The peptide and resin (0.84 g) were transferred to a reaction
vessel. The A-Chain analog was cleaved from the resin using HF in the presence of p-
cresol (10 mL HF/1 mL p-cresol) in an ice bath for one hour. After HF removal, the
residue was suspended in ether and filtered. Three different solutions were used to extract
the peptide: TFA aqueous, 70% HCOOH and NH4HCO3 pH 8.
2.3. Purification of A-Chain analogues: A-Chain D12C(Acm)6,7,11C(SH)20 (a) and
A-Chain D12C(Acm)6,7,11C(SSO3-)20 (b)
Degradation studies
In order to purify the A-Chain analogues and to make chain combinations, it was first
necessary to study the degradation of the peptide under basic conditions. 1 mg/mL
solutions of the peptide in 0.1 M glycine at pH 8.5, 9.3 and 10.5 were left overnight at
room temperature. The solutions were analyzed by HPLC (gradient A).
Purification of A-Chain D12C(Acm)6,7,11
A-Chain D12C(Acm)6,7,11C(SSO3-)20 (b, molecular weight: 2703.99 g/mol) was necessary
to obtain, so sulfitolysis of 84 mg of the A-Chain D12C(Acm)6,7,11 obtained after solid
phase synthesis was carried out. The reaction mixture was purified by FPLC on a MonoQ
Semi Prep column, using gradient B. The fractions containing the peptide were collected
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and split in two equal volumes. One of those volumes was run on a RP Semi Prep column
using gradient C. The fractions containing the product were collected and lyophilized. The
product was analyzed by HPLC (gradient A).
The second volume was reacted in a 10 mM DTT solution for one hour at room
temperature, in order to cleave the sulfite bond formed at Cys20. The solution was purified
by FPLC on a Pep RP Semi Prep column using gradient C. The product was obtained
after lyophilizing the collected fractions. Its HPLC chromatogram was analyzed using
gradient A.
2.4. Purification of B-Chain C(Acm)7C(SSO3-)19(c)
144 mg of a crude material of B-Chain C(Acm)7C(SSO3-)19 prepared by David Smiley at
the DiMarchi laboratory, was sulfitolized.
The reaction mixture was purified by FPLC with a Pep RP Semi Prep column, using
gradient D while monitoring the UV at 214 nm. The fractions containing the product were
collected, lyophilized and analyzed by HPLC using gradient A.
2.5. Synthesis of Insulin analogues using A-Chain D12C(Acm)6,7,11C(SH)20(a) and
B-Chain C(Acm)7C(SSO3-)19(c)
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Formation of one interchain disulfide bond 1:1 molar ratio at room temperature, pH
8.5
1 mg (3.8 x 10-7 mol) of a was added to a solution of 1.4 mg (1 equiv) of c (molecular
weight: 3581.14 g/mol) prepared by Jonathan Meyers at the DiMarchi laboratory, in 300
mL 0.05 M NH4HCO3 pH 8.5. The reaction mixture was left at room temperature and
monitored by HPLC using gradient A after 1.5, 3 and 18 hours.
By FPLC, a Pep RP column was run, using gradient E. The solvent of the desired
fractions was removed by lyophilization and analyzed by MALDI-TOF.
Formation of one interchain disulfide bond 1:1 molar ratio at 4 °C, pH 8.5
4 mg (1.143 x 10-6 mol) of c was dissolved in 900 mL 0.05 M NH4HCO3 pH 8.5 and added
to 3 mg (1 equiv) of a. The reaction mixture was left at 4 °C and it was monitored by
HPLC using gradient A after 1.5, 3 and 24 hours.
The reaction mixture was purified with a Pep RP column, using gradient F. The fractions
containing the products were collected and lyophilized. The chromatogram of the product
was analyzed using HPLC (gradient A).
In order to confirm the identity of the product 0.5 mg was treated by sulfitolysis. The
solution was analyzed after one and half hour by HPLC (gradient A) and MALDI-TOF.
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Formation of one interchain disulfide bond 1:1 molar ratio at 4 °C, pH 2.9, 6, 7.5
and 10
The reactions were set up in the same way as the reactions made at room temperature. pH
of 2.9 and 6 were obtained preparing 1% CH3COOH/20 % CH3CN solutions. The
reactions were analyzed after 1.5 hours. The HPLC chromatograms were obtained using
gradient A.
Reactions at pH 7.5 and 10 were prepared following the conditions already mentioned.
The solutions were made using 0.05 M NH4HCO3. The reaction mixtures were left at 4 °C
and monitored by HPLC using gradient A after 1.5, 3 and 24 hours.
Formation of one interchain disulfide bond 1:2, 1:4 molar ratio at 4 °C, pH 7.5 and
8.5
2.8 mg (7.63 x 10-7mol) of c were dissolved in 475 mL 0.05 M NH4HCO3 pH 8.5. 1 mg
(0.5 equiv) of a was added as a powder. The reaction mixture was left at 4 °C. The same
procedure was followed to prepare the 0.05 M NH4HCO3 pH 7.5 reaction solution.
5.5 mg (1.52 x 10-6 mol) of c were dissolved in 812.5 mL 0.05 M NH4HCO3 pH 8.5. 1 mg
(0.25 equiv) of a was added as a powder. The reaction mixture was left at 4 °C. The same
procedure was followed to prepare the 0.05 M NH4HCO3 pH 7.5 reaction solution.
The reactions were monitored by HPLC using gradient A after 1.5, 3 and 22.5 hours.
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2.6. Synthesis of Insulin analogues using A-Chain D12C(Acm)6,7,11C(SSO3-)20(b)
and B-Chain C(Acm)7C(SH)19(d)
Formation of one interchain disulfide bond 1:1 molar ratio at room temperature, pH
8.5
1.3 mg (3.7 x 10-7mol) of d (molecular weight: 3502.14 g/mol) prepared by Jonathan
Meyers was added to a solution of 1 mg (1 equiv.) of b, in 300 mL 0.05 M NH4HCO3 pH
8.5. The reaction mixture was left at room temperature and monitored by HPLC using
gradient A after 1.5 and 3hours.
Formation of one interchain disulfide bond 1:1 and 2:1 molar ratio at 4 °C, pH 7.5
and 8.5
1.3 mg (3.7 x 10-7mol) of d prepared by Jonathan Meyers at the DiMarchi laboratory, was
added to a solution of 1 mg (1 equiv.) of b, in 300 mL 0.05 M NH4HCO3 pH 8.5. The
reaction at pH 7.5 was prepared following the same procedure but using 300 mL 0.05 M
NH4HCO3 pH 7.5 The reaction mixtures were left at 4 °C and monitored by HPLC using
gradient A after 1.5, 3 and 24 hours.
1.3 mg (3.7 x 10-7mol) of d prepared by Jonathan Meyers at the DiMarchi laboratory, was
added to a solution of 2 mg (1 equiv.) of b, in 440 mL 0.05 M NH4HCO3 pH 8.5. The
same procedure was followed to prepare the solution at pH 7.5. The reactions were left at
4 °C and monitored by HPLC using gradient A after 1.5, 3 and 24 hours.
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3. RESULTS AND DISCUSSION
3.1. Synthesis of A-Chain Insulin Analogues
It was found that TFA dissolved the peptide without dissolving the resin. The 70%
HCOOH solution needed the addition of pure HCOOH in order to dissolve the peptide
entirely. Finally, the NH4HCO3 pH 8 solution was able to dissolve the solid with the
addition of CH3CN.
HPLC analysis of the extracts were used to corroborate the presence of the A-Chain
D12C(Acm)6,7,11 in the product. The peak located at 5.8 min in each chromatogram was
confirmed to be the A-Chain desired by comparison with the HPLC chromatogram
obtained from the same peptide synthesized by David Smiley (DLS-005-91, retention
time: 5.85 min). The presence of the A-Chain analogue was also confirmed by mass
spectrometry (ESI). The spectrum showed a peak located at 2623.0 of molecular weight
(the expected mass was 2625).
The three extracts were lyophilized, and the white solids obtained were stored at 4 °C.
TFA extract gave 88. 5 mg, HCOOH extract gave 91.1 mg and NH4HCO3 pH 8 extract
gave 114 mg.
3.2. Purification of A-Chain analogues: A-Chain D12C(Acm)6,7,11C(SH)20(a) and
A-Chain D12C(Acm)6,7,11C(SSO3-)20(b)
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Degradation studies
The chromatograms showed degradation of the peptide at pH 9.3 and 10.5 with the
appearance of a second peak located at 5.6 min. Mass spectrometry (MALDI-TOF)
analysis of the pH 8.5 solution after a 30 min exposure, was compared with the mass
spectrum (MALDI-TOF) of the pH 10.5 solution left overnight. The latter spectrum did
not show the peak of 2646.1096 of molecular weight which was considered to be from the
peptide desired (the expected mass was 2625) and that appeared in the former spectrum.
A 6 hours study of a 1mg/mL solution of the peptide in 0.1 M glycine at pH 8.5 followed
by HPLC analysis confirmed that at this particular pH, degradation did not occurred.
Purification of A-Chain D12C(Acm)6,7,11
14 mg of a white solid was obtained of peptide b with a retention time of 5.35 min in its
HPLC chromatogram, whereas 15.5 mg of a white product was obtained of peptide a with
a retention time of 5.81 min in its chromatogram. The overall yield was 35 %.
3.3. Purification of B-Chain C(Acm)7C(SSO3-)19(c)
The HPLC chromatogram obtained from this product (30 mg, 21 % yield) confirmed the
presence of the peptide. It had a retention time of 6.5 min which was the same as the one
obtained with the B-Chain C(Acm)7C(SSO3-)19 prepared by Jonathan Meyers at the
DiMarchi laboratory.
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3.4. Synthesis of Insulin analogues using A-Chain D12C(Acm)6,7,11C(SH)20(a) and
B-Chain C(Acm)7C(SSO3-)19(c)
Formation of one interchain disulfide bond 1:1 molar ratio at room temperature, pH
8.5
The chromatograms showed the formation of two products with retention times of 6.68
and 7.1 min. By comparison with the HPLC analysis of a monodisulfide insulin
synthesized by David Smiley (DLS-005-67B) (Figure 2, a) it was determined that the
peak that appeared at 6.68 min corresponded to the desired product. MALDI-TOF
analysis of the reaction after 3 hours confirmed the presence of the dipeptide. It showed a
peak of M+1 of 6125.059 of molecular weight (the expected molecular weight was 6124).
Two fractions obtained during the purification of the reaction mixture, were analyzed by
MALDI-TOF. It was found that the peak that appeared on analytical HPLC (gradient A)
with retention time of 6.68 min (Figure 2, c) was effectively the dipeptide desired
showing a molecular weight of M+1 of 6125.1 (Figure 3, a), whereas the peak that
appeared at 7.1 min (Figure 2, b) was found to be a B-chain dimer with a molecular
weight of M+1 of 7001.6 (Figure 3, b).
a)
b)
c)
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Figure 2 a) Monodisulfide insulin synthesized by David Smiley (DLS-005-67B), b)
Fraction ACI 20-2 from chromatography, c) Fraction ACI20-1 from
chromatography.
Figure 3 a) Fraction ACI20-1 from chromatografphy, b) Fraction ACI 20-2 from
chromatography.
In the MALDI-TOF the B-Chain d was shown with molecular weight of M+1 of 3502.6.
From this reaction less than one milligram was obtained which corresponds to less than 15
% yield.
a) b)
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With these results it was concluded that the active Cys(SH)20 group of the A-Chain a
attacked the interchain disulfide once formed releasing one molecule of B-chain containing
an active thiol capable of react with the c peptide by thiolysis, leading to the formation of
the B dimer. A reaction made at less temperature, in a more acidic solution, or using less
amount of the active compound was thought to decrease the activity of the thiol group
present at A20 accompanied by a decrease in the formation of the B dimer.
Formation of one interchain disulfide bond 1:1 molar ratio at 4 °C, pH 8.5
From the chromatograms obtained it was found that the ratio between the peak of the
dipeptide desired (6.7 min of retention time, Figure 4, a) and the one that corresponded
to the B dimer was bigger than the same ratio observed when the reaction was made at
room temperature (Figure 4, b). This confirmed that the nucleophilicity of the Cys(SH)20
group found in the A-Chain was reduced at 4 °C.
a)
b)
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Figure 4 a) Formation of one interchain disulfide bond 1:1 molar ratio at 4 °C, pH
8.5 after 18 h, b) Formation of one interchain disulfide bond 1:1 molar ratio at room
temperature, pH 8.5 after 22 hours.
The identity of the purified product was confirmed by MALDI-TOF (Figure 5, a) and by
inspection of the chromatograms obtained after sulfitolysis. These showed the presence of
a and c, which were separated from the monodisulfide insulin (Figure 5, b and c).
Figure 5 a) MALDI-TOF of the purifed product, b) HPLC chromatogram of the
product, c) A-chain and B-chain separated after sulfitolysis of the product.
In this reaction 1.1 mg was obtained which represented 20 % yield.
Formation of one interchain disulfide bond 1:1 molar ratio at 4 °C, pH 2.9, 6, 7.5
and 10
a)
b)
c)
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At pH 2.9 peptide b could be dissolved but peptide a could not be dissolved, whereas at
pH 6, a was soluble but b wasn’t.
At pH 2.9 the only peak observed was the one that correspond to the B-Chain whereas at
pH 6 just the peak corresponding to A-Chain was obtained.
From these results it was concluded that the lack of solubility of the reagents prevent the
reaction  take place.
From the HPLC chromatograms it was found that at pH 10 the reaction didn’t take place.
At pH 7.5 and after 24 hours the intensity of the peak that corresponds to the product
desired (retention time of 6.8 min) was bigger than the one that was thought to be the B
dimer (retention time of 7.2 min) (Figure 6) .
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Figure 6. Formation of one interchain disulfide bond 1:1 molar ratio at 4 °C, pH 7.5.
With these results it was confirmed that the nucleophilicity of the Cys(SH)20 was reduced
in a more acidic environment.
Formation of one interchain disulfide bond 1:2, 1:4 molar ratio at 4 °C, pH 7.5 and
8.5
From the chromatograms it can be concluded that the reaction using a:c/1:4, didn’t give a
considerable amount of product, neither at pH 7.5 nor at pH 8.5. After 22.5 hours it could
be noted that the reaction did take place reflecting the slow rate or the reaction.
The best results were obtained using a:c/1:2 at pH 7.5 after 22.5 hours. However, the
peak that corresponded to the dipeptide obtained (retention time of 6.8 min) had the same
intensity as the peak that corresponded to the B-Chain (retention time of 6.6 min) (Figure
7).
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a)
Figure 7. Formation of one interchain disulfide bond 1:2 molar ratio at 4 °C, pH 7.5
3.5. Synthesis of Insulin analogues using A-Chain D12C(Acm)6,7,11C(SSO3-)20(b)
and B-Chain C(Acm)7C(SH)19(d)
Formation of one interchain disulfide bond 1:1 molar ratio at room temperature, pH
8.5
The chromatograms showed three significant peaks. The peak that appeared at 6.8 min
corresponded to the desired product. B-chain d (6.9 min) and B dimer (7.1 min) were also
shown. Because the three peptides eluted with similar retention times the purification of
the desired one could be a difficult step.
Formation of one interchain disulfide bond 1:1 molar ratio at 4 °C, pH 7.5 and 8.5
The chromatograms showed that a considerable amount of product did not form under
these conditions.
Formation of one interchain disulfide bond 1:1 and 2:1 molar ratio at 4 °C, pH 7.5
and 8.5
The chromatograms showed that using b:d/2:1 molar ratio more product was obtained (in
comparison with the starting materials) than using a 1:1 molar ratio.
At pH 8.5 (2:1 molar ratio) it was obtained a greater amount of product (retention time of
6.6 min) in comparison with the one obtained at pH 7.5 (Figure 8).
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Figure 8 a) Formation of one interchain disulfide bond 2:1 molar ratio at 4 °C, pH
8.5, after 3 hours b) Formation of one interchain disulfide bond 2:1 molar ratio at 4
°C, pH 7.5, after 4 hours.
4. CONCLUSIONS
Extraction of the peptide using a NH4HCO3 pH 8 solution was found to give good
amounts of  crude A-chain after its solid phase synthesis.
A-chain degradates at pH 9.3 and 10.5 but it remains stable on a pH 8.5 0.1 M glycine
solution.
The procedures used to purify the A-Chain and B-Chain after their chemical synthesis
were successful. The purity of the peptides was confirmed by HPLC and Mass
Spectrometry analysis.
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The formation of the interchain disulfide bond was successfully obtained using step 4 from
Scheme 1. The identity of the peptide was confirmed by HPLC and Mass Spectrometry
analysis.
In the formation of the interchain disulfide bond between A-Chain D12C(Acm)6,7,11C(SH)20
and B-Chain C(Acm)7C(SSO3-)19 it was found that the reaction needs to take place at 4 °C
and in a slightly acidic solution in order to decrease the activity of the thiol group present
at A20 that cause the formation of B dimer. By inspection of the data it could be obtained
a better yield making the reaction at pH 7.5 with a 1:1 molar ratio of the peptides at 4 °C.
It is also important to mention that the reaction does not take place at pH 2.9 nor at pH 6
due to the lack of solubility of the peptides.
In the formation of the interchain disulfide bond between A-Chain D12C(Acm)6,7,11C(SSO3-
)20 and B-Chain C(Acm)7C(SH)19 it was found that making the reaction at 2:1 molar ratio,
4 °C and pH 8.5 gave a product with less amount of side products.
Finally, among all the conditions, the reaction make between A-Chain
D12C(Acm)6,7,11C(SH)20 and B-Chain C(Acm)7C(SSO3-)19 on a pH 7.5 solution with a 1:1
molar ratio of the peptides at 4 °C was found to be the best option.
5. FUTURE WORK
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A new reaction between A-Chain D12C(Acm)6,7,11C(SH)20 and B-Chain C(Acm)7C(SSO3-
)19 using the set of conditions found should be carried out. The product should be purified
and characterized by HPLC and Mass Spectrometry analysis. The amount of product
should be quantified in order to determine the overall yield. If the yield obtained is good, a
large scale reaction should be carried out in order to proceed with step 5 in the process
shown in Scheme 1.
A new set of reactions should be carried out in which the overall concentration of the
peptides should be decrease in order to determine its effects in the formation of the
dipeptide. This could decrease the amount of side products obtain during the reaction.
178
REFERENCES
1. De Meyts, P; Whittaker, J. Drug Discovery. 2002, 1, 769-783.
2. Berg, J; Tymoczko, J; Stryer, L. Biochemistry 5th edition 2002, 858-859.
3. De Meyts, P. BioEssays. 2004, 26, 1351-1362.
4. DeWitt, D; Hirsch, I. JAMA, 2003, 289, 2254-2264.
5. Hirsch, I. N. Engl. J. Med. 2005, 352(2), 174-183.
6. Information available at
http://www.lillydiabetes.com/product/humulin_family.jsp?reqNavId=5.3, April 2006.
7. Buse, J. Current Opinion in Endocrinology & Diabetes. 2001, 8, 95-100.
8. Sieber, P; Kamber, B; Hartmann, A; Johl, A; Riniker, B; Rittel, W. Helv. Chim. Acta
1977, 60, 27-37.
9. Akaji, K; Fujino, K; Tatsumi, T; Kiso, Y. J. Am. Chem. Soc. 1993, 115, 11384-11392.
10. Bathgate, R; Lin, F; Hanson, N; Otvos, L; Guidolin, A; Giannaskis, C; Bastiras, S;
Layfield, S; Ferraro, T; Ma, S; Zhao, C; Gundalach, A; Samuel, C; Treagear, G; Wade, J.
Biochemistry. 2006, 45, 1043-1053.
